Company intelligence / Profile preview
PALA Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
Overview
PALA Pharmaceuticals is a biotechnology company focused on repurposing the small molecule PALA (N-phosphonacetyl-L-aspartate) for oncology and infectious diseases. Originally developed in the 1970s as a high-dose metabolic inhibitor, PALA has been rediscovered as a potent immune activator at low, safe doses. The company's lead programs utilize systemic and topical delivery methods to block the CAD protein, which in turn activates the NOD2 immune pathway to enhance the body's anti-tumor and antimicrobial responses.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on PALA Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PALA Pharmaceuticals.